Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836447 | 0.82 | ALDH1A1 (0.41) | ALDH1A1PTGS2CYP11B1CYP11B2ATM | |
| SCHEMBL28073055 | 0.82 | CYP2A6 (0.42) | ALDH1A1KMT2ACYP11B1CYP11B2ATM | |
| SCHEMBL27981339 | 0.82 | HSD17B10 (0.42) | ALDH1A1PKMPTGS2HTTCYP11B1 | |
| SCHEMBL7563960 | 0.81 | ATM (0.53) | ALDH1A1PKMHTTCYP11B1CYP11B2 | |
| SCHEMBL16099492 | 0.78 | CYP11B2 (0.58) | PKMCYP11B1CYP11B2 | |
| SCHEMBL14167337 | 0.78 | CYP11B1 (0.41) | ALDH1A1CYP11B1CYP11B2ATMMGLL | |
| SCHEMBL10589324 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KMT2AHTTNPC1RAB9A | |
| SCHEMBL17940683 | 0.73 | HCAR1 (0.37) | ALDH1A1CYP11B1CYP11B2SMN1; SMN2KDM4E | |
| SCHEMBL29691103 | 0.72 | CYP11B1 (0.39) | PKMKMT2AHTTCYP11B1CYP11B2 | |
| SCHEMBL7700254 | 0.71 | CYP11B1 (0.67) | ALDH1A1PKMCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498354-B2 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498354-B2 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498354-B2 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1883638-A1 | PYRROLO [2,3-D] IMIDAZOLES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | OSI Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006107756-A1 | PYRROLO [2,3-D] IMIDAZOLES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | OSI PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223799-A1 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | ALDH1A1 484/4885PKM 4263/4885PTGS2 2804/4885 |
| US-20060223799-A1 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | PPOX, VHL, TP53 | ALDH1A1 1280/4885PKM 2568/4885PTGS2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.